Review article: Defining remission in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 2, 2011, Pages 113-124

  Travis, S P L ^a   Higgins, P D R ^b   Orchard, T ^c   Van Der Woude, C J ^d   Panaccione, R ^e   Bitton, A ^f   O'Morain, C ^g   Panes J ^h   Sturm, A ⁱ   Reinisch, W ^j   Kamm, M A ^k,l   D'Haens, G ^m  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ST MARY S HOSPITAL   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALGARY   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

^h INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k ST VINCENT S HOSPITAL   (Australia)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; LACTOFERRIN; LEUKOCYTE ELASTASE; MESALAZINE;

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE DURATION; HEALING; HISTOPATHOLOGY; HUMAN; INTESTINE ENDOSCOPY; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80955180936     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04701.x     Document Type: Review

References (67)

1. Travis SPL, Dinesen L,. Remission in trials of ulcerative colitis-what does it mean? Pract Gastroenterol 2006; 30: 17-20. (Pubitemid 46032827)
2. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008; 2: 1-23. (Pubitemid 351179487)
3. Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP,. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials 2007; 8: 17-22.
4. Katz S,. "Mind the Gap": an unmet need for new therapy in IBD. J Clin Gastroenterol 2007; 41: 799-809. (Pubitemid 47442704)
5. Katz S, Higgins P, Eusebio R, Yacyshyn B,. Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores. Gastroenterology 2006; 130 (Suppl. 2): A-482.
6. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
7. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5. (Pubitemid 24188135)
8. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955; 2: 1041-8.
9. Baron JH, Connell AM, Lennard-Jones JE,. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964; 1: 89-92.
10. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE,. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-7. (Pubitemid 12120288)
11. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9. (Pubitemid 18010466)
12. Rutegard I, Ahsgren L, Stenling R, Nilsson T,. A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology 1990; 37 (Suppl. 2): 110-2.
13. Rachmilewitz D,. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6. (Pubitemid 19032930)
14. Kruis W, Kiudelis G, Rácz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-40.
15. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-8. (Pubitemid 17072238)
16. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5. (Pubitemid 40873909)
17. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM,. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-8. (Pubitemid 40732094)
18. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
19. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR,. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516-26.
20. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85.
21. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75. (Pubitemid 46108735)
22. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ,. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-7. (Pubitemid 36886241)
23. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21: 827-34. (Pubitemid 351255702)
24. Walmsley RS, Ayres RC, Pounder RE, Allan RN,. A simple clinical colitis activity index. Gut 1998; 43: 29-32. (Pubitemid 28335486)
25. Colombel JF, Rutgeerts P, Reinisch W, et al. Mucosal healing in patients with ulcerative colitis associates with a reduced colectomy risk, high incidence of symptomatic remission and corticosteroid-free state. Gut 2010; 59: A411 (Abstract P1511).
26. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-9.
27. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 1111-9. (Pubitemid 40646537)
28. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902. (Pubitemid 351919522)
29. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1-8.
30. Burger D, Thomas SJ, Walsh AJ, et al. Depth of remission may not predict outcome of ulcerative colitis over 2 years. J Crohn's Colitis 2011; 5: S4-5.
31. Higgins P, Schwartz M, Mapili J, Zimmermann EM,. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis. Am J Gastroenterol 2005; 100: 355-61. (Pubitemid 40314520)
32. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ,. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-9.
33. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M,. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-6.
34. Seo M, Okada M, Yao T, Okabe N, Maeda K, Oh K,. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts classification. Am J Gastroenterol 1995; 90: 1759-63.
35. Seo M, Okada M, Maeda K, Oh K,. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol 1998; 93: 2124-9. (Pubitemid 29076862)
36. Seo M, Okada M, Yao T, Matake H, Maeda K,. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 37: 29-34. (Pubitemid 34144959)
37. Bewtra M, Su C, Lewis JD,. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007; 5: 597-601.
38. Lichtenstein GR, Rutgeerts P,. The importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16: 338-46.
39. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112-24.
40. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
41. Carter MJ, Lobo AJ, Travis SPL,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: v1-16. (Pubitemid 39120096)
42. Rutgeerts P, Vermeire S, Van Assche G,. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453-5. (Pubitemid 46580492)
43. Frøslie KF, Jahnsen J, Moum BA, Vatn MH,; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22. (Pubitemid 47187355)
44. Egan LJ, Everett SM, Rutgeerts P,. Re-defining outcomes and re-evaluating remission in inflammatory bowel disease: assessing key evidence. Biologics 2008; 2 (Suppl. 1): 1-14.
45. Kane S,. Endoscopic healing should be a goal for everyone with ulcerative colitis. Inflamm Bowel Dis 2008 [Epub ahead of print].
46. Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC:NORMAL survey. Inflamm Bowel Dis 2009; 15: 581-8.
47. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastrenterol 2007; 102: 794-802. (Pubitemid 46496629)
48. Lakatos L, Lakatos PL,. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J 2006; 82: 270-3.
49. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME,. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
50. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20. (Pubitemid 32061864)
51. Rubin DT, Huo D, Hetzel JT, et al. Increased degree of histological inflammation predicts colectomy and hospitalisation in patients with ulcerative colitis. Gastroenterology 2007; 132 (Suppl. 1): A-19 (Abstract 103).
52. Thomas SJ, Walsh AJ, Von Herbay A, et al. How much agreement is there between histological, endoscopic and clinical assessments of remission in ulcerative colitis. Gut 2009; 58 (Suppl. 1): A101.
53. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-8.
54. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I,. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22. (Pubitemid 30452574)
55. Gray JR, Leung E, Scales J,. Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther 2009; 29: 1114-20.
56. Joyce JC, Waljee AK, Khan T, et al. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health Qual Life Outcomes 2008; 6: 69.
57. Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD,. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol 2009; 21: 558-64.
58. Kane S, Huo D, Aikens J, Hanauer S,. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43. (Pubitemid 36126514)
59. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol The 2006; 23: 577-85.
60. Hawthorne AB, Rubin G, Ghosh S,. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27: 1157-66. (Pubitemid 351697281)
61. Prantera C, Rizzi M,. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009; 15: 4353-5.
62. Chaudhary N, Junior J, Tukey M, Falchuk KR, Cheifetz A, Moss AC,. Impact of a patient support program on mesalamine adherence in patients with ulcerative colitis. Gastroenterology 2009; 136 (S1): S1053.
63. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC,. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22-33.
64. Cross RK, Cheevers N, Finkelstein J,. Home telemanagement for patients with ulcerative colitis (UC HAT). Dig Dis Sci 2009; 54: 2463-72.
65. Kane SV, Brixner D, Rubin DT, Sewitch MJ,. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm 2008; 1 (Suppl. A): s2-12. (Pubitemid 351276789)
66. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV,. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29: 247-57.
67. Kripalani S, Yao X, Haynes RB,. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-50. (Pubitemid 46513223)